http://www.neurology.org/content/82/...t/P3.155.short

Study has been going approx. 1 year,

Pilot Trial Of Recombinant Human Growth Hormone For Remyelination In Multiple Sclerosis: Current Status And Preliminary Safety Analysis (P3.155)

Dr. Then Bergh has received personal compensation for activities with Biogen Idec, Novartis, Merck Serono, and Sanofi-Aventis Pharmaceuticals Inc. as a speaker or member of an advisory board. Dr. Then Bergh has received research support from Bayer Schering, Novartis and Teva Neuroscience.

In other words, every large Pharma is interested in the outcome of this one.. I am too.